Ketamine is a breakthrough treatment in psychiatry, with mounting real-world evidence showing its efficacy in offering relief for treatment-resistant depression. The excitement surrounding psychedelic medicine brings hope, but also legal challenges for clinicians.

‍

Daniel Sternthal and Ethan Minkin are legal experts with a decade of experience observing practice patterns among ketamine clinicians and legal challenges. They'll guide us through strategies to safeguard practitioners in this evolving landscape.

‍

‍

The Rise of Ketamine Therapy

Ketamine therapy has emerged as a promising treatment for various psychiatric conditions, transitioning from an anesthetic to a key player in the treatment of treatment-resistant depression. This shift underscores the need for psychiatrists to be well-versed in the legal aspects of providing such treatments.

‍

Evolution and Current Trends

Since community clinics began opening, particularly around 2010, ketamine therapy has seen a significant surge in interest. Daniel notes, "I've seen trends develop since that time... there's an initial great interest in the field, which leads to lots of people getting involved." This wave of enthusiasm led to a boom around 2017, with a noticeable increase in clinic openings and investment interest, especially from the private equity space.

‍

However, the landscape began to shift with the advent of COVID-19. The pandemic introduced a slowdown in deals and heightened hesitancy among potential investors. Daniel reflects on this period as one of "deferred care," crucial for patients who might benefit from ketamine therapy.

‍

Post-COVID, while interest remains, there's been a "more muted level" of activity, with fewer private equity groups investing in the space. This cooling trend speaks to a broader caution in the healthcare investment community, partly due to the complexities of integrating ketamine therapy into traditional healthcare models.

‍

Economic Forces and Clinic Viability

Economic pressures, including investment shifts and the financial sustainability of clinics, are significant concerns. The interplay between private equity expectations and healthcare delivery realities has led to instances of insolvency within the field. Daniel's insights suggest a cautious approach to financial planning and partnerships, emphasizing the importance of aligning clinic operations with sustainable business models.

‍

Navigating Distribution Challenges

Recent years have seen challenges in drug distribution, with some manufacturers and distributors becoming more conservative in their approach to supplying ketamine clinics. Issues of drug shortages and selective distribution practices have arisen, influenced by broader industry trends and previous litigations, like the opioid crisis.

‍

Distributors are now enforcing stringent "Know Your Customer" policies to mitigate liability, which involves thorough due diligence on pharmacies and healthcare providers to ensure ketamine is used appropriately. Anecdotal evidence suggests that these suppliers prefer dealing with providers who are "perfect on paper," often defined as physicians with significant psychiatric or mental health experience.

‍

These dynamics necessitate a proactive approach to secure reliable drug supply chains, ensuring your clinic can consistently provide care. Clinics on the Osmind platform have priority access to certain compounding pharmacies and distributors.

‍

Protect your Ketamine Clinic from Malpractice

‍

Off-Label Ketamine Use

The off-label application of ketamine poses legal nuances that clinicians must navigate carefully. Without large-scale randomized clinical trials backing its use for certain conditions, psychiatrists need to critically assess the existing evidence and ensure that their treatment decisions are well-informed and legally defensible.

‍

Minkin explains, “There are a tremendous number of medications in the United States that are prescribed in an off-label manner, and there's absolutely nothing illegal about that at all. I think even in the FDCA, the FDA Act, it recognizes that as well.”

‍

"Ketamine, I think, has different legal risks than the other psychedelics that are currently under clinical trials with the FDA," This lack of definitive research places a burden on clinicians to judiciously assess the evidence supporting ketamine's efficacy for specific psychiatric disorders to mitigate legal risk.

‍

Cite the Research to Protect Yourself

Given these challenges, Minkin recommends a proactive and cautious approach: "I recommend to providers that if this is a drug they want to use, that they satisfy themselves that the research is strong enough that this is a good indication to use ketamine or another drug." Psychiatrists must be diligent in their review of the evidence, mindful of the legal landscape, and committed to the ethical principles guiding patient care.

‍

Setting Standards with Professional Organizations

The American Society of Ketamine Physicians (ASKP3) has emerged as a key player in establishing standards and guidelines for ketamine therapy. Their efforts aim to mainstream ketamine therapy methodologies, ensuring safe and effective treatment protocols are widely adopted. Our Chief Medical Officer, Carlene MacMillan, M.D., and VP of Life Sciences, Alison McInnes, M.D., are expert faculty of ASKP3. Engaging with such organizations can provide you with valuable resources, education, and support as you navigate the ketamine therapy landscape.

‍

Mitigating Legal Risks with Documentation and Informed Consent

To mitigate legal risks, it is imperative to adopt strategies such as ensuring informed consent, maintaining comprehensive documentation, and adhering to best practices in patient care. When in doubt, document everything. These measures not only protect the clinician but also ensure the patient's safety and trust in the treatment process.

‍

At Home Ketamine Use: Ethical and Practical Considerations

The shift towards home-based ketamine treatments, particularly oral ketamine, raises significant ethical and practical concerns. The FDA has expressed worries about patient monitoring and the potential for misuse, highlighting the need for careful consideration and robust protocols to ensure patient safety. "The usage of an oral ketamine... may lead to a tolerance issue," Sternthal warns, underscoring the risk of abuse and the importance of stringent oversight.

‍

“If you have a patient who's at home with the medication and they're not getting the same reaction that they're used to (in the clinic with IV ketamine), there's a higher likelihood of potential abuse and inappropriate usage of the, of the medicine.

‍

I love the idea of improving accessibility and reducing barriers. But I think we have to be thoughtful about how we do that and not jeopardize patient safety along the way.”

‍

Collaborative Care and Compliance in Ketamine Therapy

If you're a non-psychiatric specialist, such as an anesthesiologist, CRNA, or emergency medicine physician, exploring the potential of ketamine therapy for your patients, it's essential to approach this innovative treatment with a comprehensive understanding of both clinical and legal considerations.

‍

"I think everybody brings something of value to the table...the trick is just trying to develop an environment in which everybody respects the other's specialty and expertise," Minkin states. "To reduce exposure, they should ensure that the patient is receiving the full panoply of behavioral health treatments, including talk therapy and the like.”

‍

A collaborative model not only enriches the care provided but also aligns with legal and ethical standards by ensuring that patients receive well-rounded, expert-informed treatment.

‍

Practical Steps for Implementation

1. Integrate Behavioral Health Treatments: Ensure that patients undergoing ketamine therapy have access to comprehensive behavioral health services, including counseling or psychotherapy.
2. Foster Interdisciplinary Collaboration: Actively seek partnerships with psychiatrists and other mental health professionals to create a supportive network for patients.
3. Stay Informed and Educated: Engage with professional societies, attend conferences, and participate in continuing education to remain abreast of the latest developments and guidelines in ketamine therapy.
4. Document Thoroughly: Maintain meticulous records of treatment plans, informed consent, and patient outcomes to ensure both clinical efficacy and legal compliance.
5. Prioritize Patient Safety: Adopt protocols that safeguard patient well-being, especially concerning treatment administration and monitoring post-therapy. “Do no harm” is your north star.

‍

By embracing these guidelines, non-psychiatric specialists can effectively navigate the complexities of offering ketamine therapy, ensuring their practice is legally sound and aligned with the highest standards of patient care.

‍

The Future of Ketamine Therapy

‍

Insurance, Reimbursement, and Regulatory Trends in Ketamine Therapy

The realm of ketamine therapy, particularly within psychiatric care, is on the cusp of significant changes, especially concerning insurance, reimbursement, and regulatory frameworks. Lack of widespread insurance coverage means patients must navigate prior authorization processes or face substantial out-of-pocket expenses. This situation presents a barrier to access, making it difficult for patients to receive life-saving care.

‍

Read also: The state of breakthrough treatments

‍

Insurance access may improve as real-world evidence for ketamine mounts, and other psychedelic treatments move towards FDA approval

There's optimism that the landscape will shift favorably as other psychedelic therapies, such as MDMA and psilocybin, move closer to FDA approval. The anticipation is that these developments will pave the way for broader insurance coverage for ketamine therapy. "I think that will change over time, and I think we'll see more insurance access, once MDMA and psilocybin receive FDA approval...it'll show efficacy, which is what insurers want to see before they're going to pay."

‍

Conclusion

The journey through the legal and ethical landscape of ketamine therapy in psychiatry is complex but navigable with the right knowledge and tools. By staying informed, prioritizing interdisciplinary collaboration, and adhering to best practices in patient care and legal compliance, psychiatrists can confidently offer ketamine treatments. Let this guide serve as a beacon, encouraging a proactive stance in legal and ethical practice management, ensuring the safe and effective implementation of ketamine therapy in psychiatric care.